Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations
Chuan Zhou, Zisheng Fan, Zehui Zhou, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 5, pp. 3923-3942
Closed Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xin Xie, Tingting Yu, Xiang Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 151
Annual review of PROTAC degraders as anticancer agents in 2022
Xiao Wang, Zhao-Long Qin, Na Li, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116166-116166
Closed Access | Times Cited: 53
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
Aphrothiti J. Hanrahan, Ziyu Chen, Neal Rosen, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 3, pp. 224-247
Closed Access | Times Cited: 38
Targeting KRAS in pancreatic cancer
Sandra Stickler, Barbara H. Rath, Gerhard Hamilton
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 5, pp. 799-805
Open Access | Times Cited: 18
Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRASG12D
Chuan Zhou, Zisheng Fan, Yuejiao Gu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 2, pp. 1147-1167
Closed Access | Times Cited: 15
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction
John M. Ketcham, Jacob R. Haling, Shilpi Khare, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 14, pp. 9678-9690
Open Access | Times Cited: 63
PROTAC therapy as a new targeted therapy for lung cancer
Jennifer W. Li, Guangrong Zheng, Frederic J. Kaye, et al.
Molecular Therapy (2022) Vol. 31, Iss. 3, pp. 647-656
Open Access | Times Cited: 44
A beginner’s guide to current synthetic linker strategies towards VHL-recruiting PROTACs
Nikol A. Zografou-Barredo, Alex J. Hallatt, J. S. JUN. RICCI, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 88-89, pp. 117334-117334
Open Access | Times Cited: 31
Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach
Qiuxia Chen, Chuan Liu, Wei Wang, et al.
ACS Chemical Biology (2023) Vol. 18, Iss. 1, pp. 25-33
Open Access | Times Cited: 29
Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers
Zehui Zhou, Guizhen Zhou, Chuan Zhou, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 6, pp. 4197-4214
Closed Access | Times Cited: 23
Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions
Yanguo Shang, Shengnan Fu, Qingjing Hao, et al.
Bioorganic Chemistry (2024) Vol. 144, pp. 107092-107092
Closed Access | Times Cited: 9
Development of SOS1 Inhibitor-Based Degraders to Target KRAS-Mutant Colorectal Cancer
Yujia Bian, Diego Alem, Francisca Beato, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16432-16450
Open Access | Times Cited: 32
Discovery of BWA-522, a First-in-Class and Orally Bioavailable PROTAC Degrader of the Androgen Receptor Targeting N-Terminal Domain for the Treatment of Prostate Cancer
Bowen Zhang, Chang Liu, Zhenqian Yang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 16, pp. 11158-11186
Closed Access | Times Cited: 17
Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
Victor Hugo Fonseca de Jesus, Maria Cecília Mathias-Machado, João Paulo Fogacci de Farias, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 5015-5015
Open Access | Times Cited: 17
Current advances and development strategies of targeting son of sevenless 1 (SOS1) in drug discovery
Jialin Wu, Xiaoxue Li, Chengyong Wu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116282-116282
Closed Access | Times Cited: 6
Development of Son of Sevenless Homologue 1 (SOS1) Modulators To Treat Cancers by Regulating RAS Signaling
Guangmei Luo, Bingrui Wang, Qiangqiang Hou, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 7, pp. 4324-4341
Closed Access | Times Cited: 15
Design, Synthesis, and Bioevaluation of Pyrido[2,3-d]pyrimidin-7-ones as Potent SOS1 Inhibitors
Meiying Liu, Guizhen Zhou, Wenhong Su, et al.
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 2, pp. 183-190
Open Access | Times Cited: 13
Discovery of Potent SOS1 PROTACs with Effective Antitumor Activities against NCI-H358 Tumor Cells In Vitro/In Vivo
Xudong Pang, Dawei Cui, Binhua Lv, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 2, pp. 1563-1579
Closed Access | Times Cited: 5
A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C Inhibitor
Yan Lv, Zixuan Yang, Yiming Chen, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2487-2511
Closed Access | Times Cited: 5
Current status of cancer genome medicine for pancreatic ductal adenocarcinoma
Toshifumi Doi, Takeshi Ishikawa, Michihisa Moriguchi, et al.
Japanese Journal of Clinical Oncology (2025)
Closed Access
A Comprehensive Overview of Protacs Targeting Hsp90 and Their Client Proteins for Cancer Therapy
Gulshan Kumar, Gouri Tyagi, Vikramdeep Monga
(2025)
Closed Access
Recent advances in targeted degradation in the RAS pathway
Zhiming Ge, Zisheng Fan, Wei He, et al.
Future Medicinal Chemistry (2025), pp. 1-16
Closed Access
SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRAS G12D inhibitor in KRAS LUAD
Fernando C. Baltanás, Maximilian Kramer‐Drauberg, Rósula García‐Navas, et al.
Proceedings of the National Academy of Sciences (2025) Vol. 122, Iss. 11
Open Access
Targeting KRAS-G12C in Lung Cancer: The Emerging Role of PROTACs in Overcoming Resistance
Kumarappan Chidambaram, Arcot Rekha, Ahsas Goyal, et al.
Pathology - Research and Practice (2025), pp. 155954-155954
Closed Access
TACkling Cancer by Targeting Selective Protein Degradation
María del Mar Noblejas‐López, David Tébar-García, Raquel López-Rosa, et al.
Pharmaceutics (2023) Vol. 15, Iss. 10, pp. 2442-2442
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top